Alves Larissa Pereira, Oliveira Kevin da Silva, Santos Ana Cláudia Gonçalves Dos, Melo Demis Ferreira de, Moreira Lívia Maria Coelho de Carvalho, Oshiro Junior João Augusto, Silva Dayanne Tomaz Casimiro da, Cavalcanti Airlla Laana de Medeiros, Damasceno Bolívar Ponciano Goulart de Lima
Graduate Program of Pharmaceutical Sciences, Paraíba State University, Campina Grande 58429-600, PB, Brazil.
Laboratory of Development and Characterization of Pharmaceutical Products, Department of Pharmacy, Paraíba State University, Campina Grande 58429-600, PB, Brazil.
Polymers (Basel). 2024 Jul 2;16(13):1898. doi: 10.3390/polym16131898.
Simvastatin (SIM) is widely prescribed to treat hyperlipidemia, despite its limitations, such as a short half-life and low oral bioavailability. To overcome these drawbacks, the development of a controlled-release formulation is desirable. This study aims to develop a microparticulate system based on cellulose acetate (ACT) obtained from Perrine to promote a controlled SIM release. SIM-loaded microparticles (SMP) were prepared using the solvent emulsification-evaporation method. Several parameters were evaluated, including particle size, surface charge, morphology, encapsulation efficiency, thermochemical characteristics, crystallinity, and in vitro release profile. ACT exhibited favorable flow properties after acetylation, with a degree of substitution values superior to 2.5, as confirmed by both the chemical route and H-NMR, indicating the formation of cellulose triacetate. The obtained SMP were spherical with an average size ranging from 1842 to 1857 nm, a zeta potential of -4.45 mV, and a high SIM incorporation efficiency (98%). Thermal and XRD analyses revealed that SIM was homogeneously dispersed into the polymeric matrix in its amorphous state. In vitro studies using dialysis bags revealed that the controlled SIM release from microparticles was higher under simulated intestinal conditions and followed the Higuchi kinetic model. Our results suggest that ACT-based microparticles are a promising system for SIM delivery, which can improve its bioavailability, and result in better patient compliance.
辛伐他汀(SIM)尽管存在诸如半衰期短和口服生物利用度低等局限性,但仍被广泛用于治疗高脂血症。为克服这些缺点,开发控释制剂是很有必要的。本研究旨在开发一种基于从佩兰获得的醋酸纤维素(ACT)的微粒系统,以促进辛伐他汀的控释。采用溶剂乳化 - 蒸发法制备了载辛伐他汀微粒(SMP)。评估了几个参数,包括粒径、表面电荷、形态、包封效率、热化学特性、结晶度和体外释放曲线。经化学方法和H - NMR证实,乙酰化后ACT表现出良好的流动性能,取代度值优于2.5,表明形成了三醋酸纤维素。所获得的SMP呈球形,平均尺寸在1842至1857 nm之间,zeta电位为 - 4.45 mV,辛伐他汀掺入效率高(98%)。热分析和X射线衍射分析表明,辛伐他汀以无定形状态均匀分散在聚合物基质中。使用透析袋进行的体外研究表明,在模拟肠道条件下,微粒对辛伐他汀的控释更高,并且遵循Higuchi动力学模型。我们的结果表明,基于ACT的微粒是一种有前景的辛伐他汀递送系统,它可以提高其生物利用度,并使患者依从性更好。